In conclusion, these results provided some theoretical basis for GLUD1 as a prognostic marker and therapeutic target for ccRCC, and suggested possible pathways in which GLUD1 may be involved as a way to affect ccRCC. This evidence concerns the gene GLUD1 and nonpapillary renal cell carcinoma.